Neurotoxizität und Langzeitauswirkungen auf die Lebensqualität durch adjuvante Taxantherapie bei Mammakarzinom

Abstract

Neurotoxicity and long-term influence of adjuvant taxane treatment on the quality of life in primary breast cancer Ilin E.1, Rössle S.1, Meisner C. 2, Junack C.1, Stumpp C.1, Breiter S.1, Brinkmann F.1, Heidemann E.1 1 Oncological Comprehensive Center Stuttgart 2 Institute of Clinical Epidemiology and Applied Biometry, University of Tuebingen Background: The increasing use of taxanes in adjuvant chemotherapies in primary breast cancer leads to an increasing occurrence of neuropathies. Long-term data collections are lacking. Methods: 449 Patients taking part in the follow-up control programme of the Oncological Comprehensive Center Stuttgart and who had received an adjuvant chemotherapy between 2004 and 2011 were asked to fill in the EORTC QLQ C-30-questionnaire and the Patient Neurotoxicity Questionnaire (PNQ). Results: We received 304 answers. 152 patients had been treated with a taxane, 28 (18.4%) of those reported a persistent peripheral sensory neuropathy (PPSN). Of 142 patients without taxane treatment 15 (10.6%) reported a PPSN (p=0,057). The evaluation of the EORTC QLQ C-30-questionnaires did not reveal any differences between the two groups. Conclusion: Although a significant peripheral sensory neuropathy of up to 7 years has been observed in the taxane-group, this seems to have no effect on the quality of live.